The collaboration involves four global research sites of Boehringer Ingelheim. Under the terms of the agreement, Graffinity will receive technology access fees and success payments for the generation of various novel small molecule hit series against multiple drug targets.
Financial details of the transaction were not disclosed.
Heidelberg, Germany-based Graffinity will apply its proprietary fragment based drug discovery technology and drug fragment chemical microarrays to identify and evolve small molecule hit structures focusing on compounds with novel modes of action.
Mathias Woker, senior vice president of business development of Graffinity, said: “This collaboration demonstrates again that Graffinity’s fragment based drug discovery technology is one of the most important and reliable alternatives to standard approaches of identifying NCEs.”